Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of the stocks that was covered in that article. Wall Street analysts believe ALT has a 288% upside potential over the next 12 months.

Altimmune, Inc.(NASDAQ:ALT) is a clinical-stage biopharmaceutical company. It focuses on developing treatments for obesity, metabolic, and liver diseases. ALT’s lead product/candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist, which is currently in clinical development for the treatment of obesity and metabolic associated steatohepatitis (MASH).

The mechanism of action for pemvidutide involves the activation of GLP-1 and glucagon receptors, aiming to mimic the effects of diet and exercise on weight loss. This includes suppressing appetite and increasing energy expenditure, while also impacting hepatic fat metabolism, potentially leading to reductions in liver fat and serum lipids. Over 500 subjects have been involved in clinical trials for pemvidutide, showcasing a favorable safety profile and significant clinical benefits. Altimmune is leveraging the differentiated clinical profile of pemvidutide to pursue additional indications, beyond obesity and MASH.

In terms of the company's financial performance, Altimmune, Inc.’s (NASDAQ:ALT) first quarterly earnings report for 2025 revealed a modest revenue of $5,000, but still higher than forecasts. Chief Executive Officer, Vipin Garg, spoke during the earnings call on the company’s investment in infrastructure to support its key product, pemvidutide. He stated:

“We announced today that we have entered into a credit facility with Hercules Capital for up to $100 million. This is strategically important as we build upon our balance sheet strength and provide flexibility to support our continued development of pemvidutide.”

Investors raised concerns about the company’s lack of cash holdings which stood at $150 million at the end of the first quarter. However, the $100 million injection mentioned by the CEO offers a ray of hope. Analysts on Wall Street following the stock continue to hold an optimistic opinion about the company’s potential. Altimmune, Inc.’s (NASDAQ:ALT) is estimated to have an average twelve-month trading price of $22.38 based on analysts’ consensus, an upside of 288.54%.

Overall, Altimmune, Inc.’s (NASDAQ:ALT) ranks 10th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of ALT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than ALT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.